IL18 and neoplasm: DLL3’s tumor-specific expression in SCLC offers a viable target, while engineering strategies such as cytokine-secreting “armored” CARs (e.g., IL-12 or IL-18 producers) show promise in overcoming TME resistance (96, 146–149).